Quarterly report pursuant to Section 13 or 15(d)

11. SEGMENTS (Tables)

v3.8.0.1
11. SEGMENTS (Tables)
 9 Months Ended
Sep. 30, 2017
Segment Reporting [Abstract]  
Summarized segment financial information

Three Months Ended September 30, 2017
    ADMA BioManufacturing   Plasma Collection Centers   Corporate   Consolidated
                 
Revenues   $ 1,879,921     $ 2,813,782     $ 35,708     $ 4,729,411  
                                 
Cost of product revenue     9,552,128       1,738,988       —         11,291,116  
                                 
Gross (loss) profit     (7,672,207 )     1,074,794       35,708       (6,561,705 )
                                 
Loss from operations     (10,532,500 )     (507,900 )     (3,387,360 )     (14,427,760 )
                                 
Other expense, net     (237,548 )     —         (537,407 )     (774,955 )
                                 
Net loss     (10,770,048 )     (507,900 )     (3,924,767 )     (15,202,715 )
                                 
Total assets     55,452,496       3,517,274       13,843,710       72,813,480  
                                 
Depreciation and amortization expense     723,098       102,263       10,710       836,071  

 

Three Months Ended September 30, 2016
    ADMA BioManufacturing   Plasma Collection Centers   Corporate   Consolidated
                 
Revenues   $ —       $ 2,902,155     $ 35,708     $ 2,937,863  
                                 
Cost of product revenue     —         1,735,771       —         1,735,771  
                                 
Gross profit     —         1,166,384       35,708       1,202,092  
                                 
Loss from operations     —         (316,202 )     (3,420,670 )     (3,736,872 )
                                 
Other expense, net     —         —         (594,367 )     (594,367 )
                                 
Net loss     —         (316,202 )     (4,015,037 )     (4,331,239 )
                                 
Total assets     —         2,707,636       24,787,750       27,495,386  
                                 
Depreciation and amortization expense     —         103,493       13,815       117,308  

 

Nine Months Ended September 30, 2017
    ADMA BioManufacturing   Plasma Collection Centers   Corporate   Consolidated
                 
Revenues   $ 2,419,144     $ 8,231,414     $ 107,125     $ 10,757,683  
                                 
Cost of product revenue     12,050,984       5,190,438       —         17,241,422  
                                 
Gross (loss) profit     (9,631,840 )     3,040,976       107,125       (6,483,739 )
                                 
Loss from operations     (13,650,801 )     (1,621,364 )     (13,494,466 )     (28,766,631 )
                                 
Other expense, net     (299,535 )     —         (1,710,007 )     (2,009,542 )
                                 
Net loss     (13,950,336 )     (1,621,364 )     (15,204,473 )     (30,776,173 )
                                 
Capital expenditures     360,000       291,194       15,263       666,457  
                                 
Depreciation and amortization expense     881,496       309,606       40,163       1,231,265  

 

Nine Months Ended September 30, 2016
    ADMA BioManufacturing   Plasma Collection Centers   Corporate   Consolidated
                 
Revenues   $ —       $ 7,226,368     $ 107,125     $ 7,333,493  
                                 
Cost of product revenue     —         4,346,433       —         4,346,433  
                                 
Gross profit     —         2,879,935       107,125       2,987,060  
                                 
Loss from operations     —         (1,177,371 )     (12,208,887 )     (13,386,258 )
                                 
Other expense, net     —         —         (1,569,785 )     (1,569,785 )
                                 
Net loss     —         (1,177,371 )     (13,778,672 )     (14,956,043 )
                                 
Capital expenditures     —         46,304       17,082       63,386  
                                 
Depreciation and amortization expense     —         311,012       40,690       351,702